

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/622,893
		Filing Date	July 17, 2003
		First Named Inventor	Chong-Sheng YUAN
		Art Unit	1646
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	12+51 Refs	Attorney Docket Number	466992001300

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form 1449, 4 pages (in duplicate), listing 80 References;
<input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages	<input type="checkbox"/> CD, Number of CD(s) _____	(51) References;
<input type="checkbox"/> Certified Copy of Priority Document(s)		Return Postcard
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	CUSTOMER NO. 25225	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Laurie L. Hill - 51,804
Signature	
Date	April 28, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 28, 2004


Signature: (Rhea Amid)



PATENT
Docket No. 466992001300

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on April 28, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Chong-Shen YUAN et al.

Serial No.: 10/662,893

Filing Date: July 17, 2003

For: METHODS AND COMPOSITIONS FOR
DETERMINATION OF GLYCATED
PROTEINS

Examiner: Unassigned

Group Art Unit: 1646

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 466992001300. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 28, 2004

Respectfully submitted,

By:



Laurie L. Hill, Ph.D.

Reg. No. 51,804

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7955

Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 466992001300

Application Number 10/622,893

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

Applicant

Chong-Sheng YUAN et al.

Filing Date July 17, 2003

Group Art Unit 1646

Mailing Date April 28, 2004

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	05/1986	4,588,684	Brake	435	68	
	2.	07/1989	4,847,195	Khanna et al.	435	7	
	3.	08/1990	4,948,729	Piatak, Jr. et al.	435	68	
	4.	07/1991	5,030,563	Schendel et al.	435	698	
	5.	08/1992	5,137,821	Sagai et al.	435	190	
	6.	12/1992	5,171,670	Kronenberg et al.	435	68.1	
	7.	07/1993	5,229,286	Jarsch et al.	435	190	
	8.	09/1993	5,244,796	Levy et al.	435	190	
	9.	05/1994	5,308,770	Jarsch et al.	435	190	
	10.	09/1994	5,344,770	Hitomi et al.	435	71.2	
	11.	01/1998	5,710,248	Grose	530	327	
	12.	01/1998	5,712,138	Kato et al.	435	189	
	13.	08/1998	5,789,221	Kato et al.	435	190	
	14.	10/1998	5,824,527	Kato et al.	435	191	
	15.	01/1999	5,856,104	Chee et al.	435	6	
	16.	03/1999	5,879,921	Cherry et al.	435	190	
	17.	03/1999	5,885,811	Hansen	435	172.3	
	18.	06/1999	5,914,250	Hansen	435	69.1	
	19.	09/1999	5,948,665	Matsukawa et al.	435	194	
	20.	09/1999	5,948,659	Kato et al.	435	189	
	21.	10/1999	5,972,671	Kato et al.	435	191	
	22.	11/1999	5,985,591	Yonehara et al.	435	28	
	23.	12/1999	6,008,006	Torrens et al.	435	23	
	24.	05/2000	6,069,297	Luzzatto et al.	800	18	
	25.	10/2000	6,127,138	Ishimaru et al.	435	23	
	26.	10/2000	6,127,345	Burnham	514	44	
	27.	02/2001	6,194,200	Rose et al.	435	320.1	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 466992001300	Application Number 10/622,893
	Applicant Chong-Sheng YUAN et al.	
	Filing Date July 17, 2003	Group Art Unit 1646
	Mailing Date April 28, 2004	

	28	09/2002	6,451,574	Brode, III et al.	435	219	
	29		US2002/009779	Meyers et al.	435	69.1	05/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	30	10/1984	EP 0 121 352	Europe				
	31	07/1986	EP 0 186,643	Europe				X
	32	10/1986	EP 0 196,864	Europe				
	33	05/1989	WO 89/03886	PCT				
	34	04/1993	WO 93/06125	PCT				
	35	09/1996	WO 96/28556	PCT				
	36	05/2000	WO 00/28041	PCT				
	37	12/1999	WO 01/47968	PCT			abstract only	
	38	03/2000	WO 01/68694	PCT			abstract only	
	39	11/2001	WO 01/90325	PCT				
	40	11/2001	WO 01/90378	PCT			abstract only	
	41	12/2001	WO 01/98472	PCT			abstract only	
	42	03/2002	WO 02/20795	PCT			abstract only	
	43	08/2002	WO 02/064760	PCT			abstract only	
	44	09/2002	WO 02/072634	PCT			abstract only	
	45	05/2003	WO 03/042389	PCT			abstract only	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 466992001300	Application Number 10/622,893
	Applicant Chong-Sheng YUAN et al.	
	Filing Date July 17, 2003	Group Art Unit 1646
	Mailing Date April 28, 2004	

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	46	Allgrove and Cockrill, Archives of Disease in Childhood, 63:418-422 (1988).
	47	Armbuster, Fructosamine: Clin. Chem., 33(12):2153-63 (1987).
	48	Baker et al., Clin. Chem., 37(4):552-556 (1991).
	49	Bastin et al., Mol. Biochem. Parasitology, 77:235-239 (1996).
	50	Baynes and Monnier (eds.), Prog. Clin. Biol. Res., 304:1-410 (1989).
	51	Biochemistry 11(9): 1726-32 (1972).
	52	Chen and Katz, BioTechniques, 25(1):22-24 (1998).
	53	Diazyme Laboratories Division, General Atomics, FAOX-TE fact sheet , 5 pages.
	54	Fossati et al., Clin. Chem. 26(2):227-231 (1980).
	55	Frederick et al., J. Biol. Chem., 265(7):3793-802 (1990).
	56	Gerhardinger et al., J. Biol. Chem., 270(1):218-224 (1995).
	57	Hardy and Randall, J. Cell Sci. Suppl., 11:29-43 (1989).
	58	Hobom et al., Dev. Biol. Stand., 84:255-262 (1995).
	59	Kouzuma et al. Clin. Chimi. Acta, 324:61-71 (2002).
	60	Kuhn et al., Mol. Gen. Genet., 167(3):235-241 (1979).
	61	Michiels et al., Trends Microbiol., 9(4):164-168 (2001).
	62	Nagelkerken et al., Electrophoresis, 18:2694-98 (1997).
	63	Olah et al., Biochem., 221:94-102 (1994).
	64	Peakman et al., Nucleic Acids Res., 20(22):6111-12 (1992).
	65	Phillipou et al., Clin. Chem. 34(8):1561-64 (1988).
	66	Prickett et al., BioTechniques, 7(6):580-584 (1989).
	67	Roesser and Yanofsky, Nucleic Acids Res., 19(4):795-800 (1991).
	68	Rudiger et al., Biotechniques, 23(1):96-97 (1997).
	69	Saier et al., FASEB J., 2(3):199-208 (1988).
	70	Sakai et al., Biosci. Biotech. Biochem., 59(3):487-491 (1995).
	71	Schleicher et al., Clin. Chem. 34(2):320-323 (1988).
	72	Sigma-Aldrich Catalog No. 82452, 1 page, printed 03/02/2004.
	73	Takahashi et al., J. Biol. Chem., 272(19):12505-7 (1997).

EXAMINER:**DATE CONSIDERED:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

